<unk> , sold under the brand name Herceptin SC among others, is a fixed-dose combination medication for the treatment of HER2-overexpressing breast cancer in adults. It is a combination of<unk>  and hyaluronidase. The most common adverse reactions include fatigue, arthralgia, diarrhea, injection site reaction, upper respiratory tract infection, rash, myalgia, nausea, headache, edema, flushing, pyrexia, cough, and pain in extremity.<unk>  was approved for medical use in the European Union in August 2013.<unk>  was approved for medical use in the United States in February 2019.
Trastuzumab/hyaluronidase
Trastuzumab emtansine
Pertuzumab/trastuzumab/hyaluronidase
Trastuzumab deruxtecan
Bortezomib/dexamethasone
Trifluridine/tipiracil
Daratumumab/hyaluronidase
Decitabine/cedazuridine